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Background: Rare single nucleotide variants play an important role in genetic diversity and heterogeneity of
specific human disease. For example, an individual clinical sample can harbor rare mutations at minor frequencies.
Genetic diversity within an individual clinical sample is oftentimes reflected in rare mutations. Therefore, detecting
rare variants prior to treatment may prove to be a useful predictor for therapeutic response. Current rare variant
detection algorithms using next generation DNA sequencing are limited by inherent sequencing error rate and
platform availability.
Findings: Here we describe an optimized implementation of a rare variant detection algorithm called RVD for use
in targeted gene resequencing. RVD is available both as a command-line program and for use in MATLAB and
estimates context-specific error using a beta-binomial model to call variants with minor allele frequency (MAF) as
low as 0.1%. We show that RVD accepts standard BAM formatted sequence files. We tested RVD analysis on
multiple Illumina sequencing platforms, among the most widely used DNA sequencing platforms.
Conclusions: RVD meets a growing need for highly sensitive and specific tools for variant detection. To
demonstrate the usefulness of RVD, we carried out a thorough analysis of the software’s performance on synthetic
and clinical virus samples sequenced on both an Illumina GAIIx and a MiSeq. We expect RVD can improve
understanding the genetics and treatment of common viral diseases including influenza. RVD is available at the
following URL:http://dna-discovery.stanford.edu/software/rvd/.
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Next generation sequencing (NGS) is currently used in a
research setting to discover novel mutations in cancer,
viral, and environmental samples. As the cost of sequen-
cing decreases, this technology is increasingly used to
assess genetic diversity both for basic research as well as
translational applications in human diseases. Citing an
example of a clinical application, rare variants occurring
in pathogens such as viruses or cancer may lead to thera-
peutic resistance. However, to ensure that causative* Correspondence: genomics_ji@stanford.edu
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reproduction in any medium, provided the ormutations do not evade detection in such a clinical set-
ting, we must improve the resolution, sensitivity and spe-
cificity of available algorithms to detect such mutations.
We present a computational tool to detect very rare muta-
tions in targeted clinical samples, available for use with
multiple next-generation sequencing technologies.
The detection level of current algorithms is limited by
the inherent error rate in next generation sequencing
technologies, generally quoted as 1-3% [1,2] or 0.25% in
[3]. CRISP [4] reports to detect variants in large pooled
data sets at 2% MAF on an Illumina GA platform but with
only 86.3% sensitivity and 97% specificity. SPLINTER [5],
a recent improvement on SNPSeeker, reliably detects
mutations at 0.1% MAF using large deviation theory but
requires both a positive and negative control. SNVer [6]
outputs significance p-values for the likelihood of a variantl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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ants in HIV with MAF as low as 0.27% but is limited by
its application on a 454 FLX Platform. By significantly
changing the sample preparation technique, Schmitt et al.
report a resolution of 1x10-9 [8].
Recently, we demonstrated an algorithm for detecting
very rare mutations in clinical samples from targeted
next-generation sequencing data [3]. The implementa-
tion of the original method required access to MATLAB
as well as extensive preprocessing to convert the data to
a usable format. Also, we used filtering that allowed no
more than two mismatches between each read and the
reference sequence, thus limiting the usefulness of the
algorithm for longer-read (>50 base pair) data sets. Here,
we provide an implementation that operates directly on
BAM formatted data files and is available as a command
line program. This program outputs a simple table of
called variants in one computational step (Figure 1). We
also increase the usefulness of our method for sequence
data of longer read length by implementing filtering of
sequence data on base quality score rather than on num-
ber of sequence mismatches. We demonstrate our algo-
rithm on samples sequences in multiple lanes of the
Illumina GAIIx platform and on samples sequenced on
the Illumina MiSeq platform.
Implementation
RVD is available as a command-line program for the
Unix platform and requires only access to samtools andFigure 1 Workflow of Rare Variant Detection (RVD) Application. The s
containing directory locations, base quality and resolution thresholds, and
specific information, a reference sequence file, and BAM format files with s
distribution is applied to estimate the error rate of reference replicates that
parameter that represents the true error rate at a single position in a single
parameters {Μ_0, μ} where μ is the prior error rate estimated at the given
output of the application is a tab-delimited text file containing, for each po
frequency (MAF) in the sample and a statistical call for significance. RVD is
low as 0.1%.the MATLAB compiler runtime (MCR), a free utility
provided with the application package. RVD users
prepare a configuration information file containing the
region of interest, resolution and base quality thresholds,
and reference sequence information as well as a sample
meta-data file containing sample information. The RVD
program package is available at http://dna-discovery.
stanford.edu/software/rvd/ and a detailed user guide is
provided in Additional file 1. RVD implements the
following basic steps.
Generate depth tables from user input BAM files
RVD sorts BAM files and converts them to samtools
pileup format files. The pileup files are then used to
generate depth tables containing base-specific coverage
at each position in the sequence. Phred scores are calcu-
lated for each base from the pileup file base quality
scores using the ASCII offset appropriate for the data
set (33 as default or may be set manually as an optional
parameter by user). Unmapped reads are removed and
the remaining reads are filtered to remove alignments
below a user-defined quality threshold.
Estimate site-specific reference error distribution
RVD estimates the context-specific error rate based on
the number of non-reference reads in each of the
sequenced reference samples. A beta-binomial model is
used to calculate a reference error rate distribution for
each position in the sequence. One of the parameters oftandalone application requires four inputs: a configuration file
region of interest information, a metadata information file with sample-
hort read sequencing data for each sample. A beta-binomial prior
are sequenced alongside samples. In the figure, θ is the binomial
experimental replicate. The variable θ has a beta distribution with
position and Μ_0 is the experimental precision of the error rate. The
sition in the reference sequence, an estimate of the minor allele
able to detect single nucleotide variants with minor allele frequency as
Table 1 Detecting rare synthetic variants across multiple
lanes
Mutant fraction of sample 0.1% 0.3% 1% 10% 100%
Sequence lane 1 2 2 3 3
Sensitivity 100% 100% 100% 100% 100%
Specificity 98.8% 100.0% 99.9% 99.8% 100%
When the reference and sample are sequenced in different lanes, rare (>0.3%)
variants are still called with high sensitivity and specificity. A 0.01% resolution
threshold and 30 base quality threshold were used, and the reference was
sequenced in Lane 1.
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cision of sample preparation. Experimental precision,
and thus performance of the algorithm, can be maxi-
mized if the same preparation techniques, batch of
reagents, and sample sequencing flow cell are used to
prepare and sequence the reference and the samples (see
Sample Preparation Requirements).
Test samples on reference error rate
RVD compares site-specific sample error rates to the
estimated reference error distributions using a p-value of
1x10-6 to call variants.
Call variants to output
RVD filters calls based on the resolution threshold and
outputs a simple call table for the region of interest of
each sample. RVD also outputs a single text file
containing information about the sequencing process
error calculated during analysis.
Methods for sample preparation
To test the effectiveness of our rare variant detection
method in clinical applications, we applied it to both the
synthetic and clinical data sets reported in [3]. The syn-
thetic DNA samples consisted of ~400 base-pair long
reference and sample sequences that were synthesized
in-vitro. The sample construct contained 14 single
nucleotide changes at known positions compared to the
reference. The sample and reference DNA were com-
bined at known molar fractions: 0%, 0.1%, 0.3%, 1%,
10%, and 100% and sequenced in triplicate on the
Illumina GAIIx to determine the accuracy of the
method.
Twelve clinical samples were obtained from
nasopharynegeal swabs of patients infected with H1N1 in-
fluenza and sequenced alongside three H1N1 neuraminid-
ase reference replicates. To test the applicability of our
method to novel technologies, we sequenced the same
clinical libraries on a MiSeq platform. We sequenced one
clinical sample (BN1) in replicate in multiplex with each
platform and between platforms, allowing us to compare
intra- and inter-platform reproducibility.
Sample preparation requirements
The algorithm is designed to account for sequencing
variation by repeated observation of the reference se-
quence. Consequently, it is important to control the
protocols of sample storage and preparation for both the
samples of interest and the reference samples. In par-
ticular, we recommend identical extraction and storage
of nucleic acids [9], starting amounts of nucleic acids,
library preparation and PCR protocols [10]. To achieve
the optimal detection threshold for variants, we also find
that the sample and reference should be sequenced onthe same flow cell, though this requirement is not
mandatory (see Table 1).Results and discussion
Setting the resolution threshold
By testing a range of resolution thresholds, we find that
an optimal threshold to jointly maximize sensitivity and
specificity is ½ of the desired MAF detection level.
Flaherty et al. reported 98% specificity and 100% sensi-
tivity on the 0.1% synthetic mixture in the previous
version of this algorithm [3]. We tested dependence of
specificity and sensitivity on resolution threshold by
computing an average specificity and sensitivity across
the three synthetic DNA replicates using a base quality
threshold of 30. We find the sensitivity decreases from
100% to 85.7% and specificity increases from 99.9% to
100% as the resolution threshold is increased from
0.01% to 0.1% (Figure 2A).
We repeated the resolution threshold scan for the
0.3%, 1%, 10%, and 100% synthetic mixtures and find
that the optimal resolution threshold for all mixtures is
consistently half of the MAF (Additional file 2: Figure
S1). For example, to optimally detect a MAF of 1%, a
resolution threshold of 0.5% should be used. If the ob-
jective is only to maximize specificity, a higher threshold
should be used. If the objective is only to maximize
sensitivity, a lower threshold should be used.Setting the base quality threshold
The base quality threshold and resolution threshold can
be adjusted to optimize the performance of the algo-
rithm (Figure 2B). Increasing the base quality threshold
had no effect on sensitivity at low (<0.05%) resolution
thresholds. However, at a higher (0.1%) resolution
threshold, increasing the base quality threshold from 0
to 30 drastically increases the sensitivity of the algorithm
from 64% to 86%. Thus, as base quality threshold
increases, RVD sensitivity becomes less dependent on
the resolution threshold.
Changing the base quality threshold does not signifi-
cantly change the specificity of the algorithm. A base











































Figure 2 Measuring sensitivity, specificity, and Matthews correlation coefficient (MCC) for optimal choice of resolution threshold and
base quality threshold. Analysis was done averaging sensitivity, specificity, and MCC across three 0.1% synthetic mixture DNA replicates
sequenced on a GAIIx platform. (A) With a base quality threshold of 30, the specificity increases slightly from 0.999 to 1 as the resolution
threshold is increased from 0.01% to 0.1%. More drastically, the sensitivity decreases at a threshold greater than 0.05% from near 1 to 0.857 at
0.1%. The MCC statistic that combines these two measures and adjusts for unequal distribution of true positives and true negatives peaks a range
of 0.02% - 0.07%, indicating an optimal resolution threshold. (B) As the base quality threshold is increased from 0 to 30, RVD sensitivity becomes
less dependent on resolution threshold. Thus, a higher base quality threshold may improve resolution of the algorithm.
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and 100% specificity for all resolution thresholds greater
than 0.01%. The lowest specificity, 99.0%, occurs at a
base quality threshold of 10 and no resolution threshold.
Because this decrease in specificity between base quality


























Figure 3 Sensitivity and specificity to detect rare variants on the MiSe
(two each in lanes 1 and 2) and variant calls made on all four replicates at
lower threshold) and a base quality threshold of 30 were considered “true”
set of true variants, and the sensitivity and specificity was averaged across
with GAIIx but no significant loss of specificity. When the resolution thresh
sensitivity decreased as expected.base quality threshold will likely not affect the overall
specificity of RVD.
As the base quality threshold is increased from 0 to
30, the average reference error rate in the synthetic
samples is reduced from 0.26% to 0.02%. Further, the
maximum base quality in the synthetic data set is 380.05 0.06 0.07 0.08 0.09 0.10 
Threshold (%) 
q platform. Four replicates of sample BN1 were run on the GAIIx
a resolution threshold of 0.01% (10x lower than a previously reported
variants. Two MiSeq BN1 replicate calls were each compared to the
the MiSeq replicates. MiSeq shows 43% loss of sensitivity compared
old for the MiSeq calls was increased from 0.01% to 0.1%, the
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quence samples. This variation in base quality between
runs suggests the optimal base quality threshold may be
run-dependent.Sequencing reference and sample in different lanes
Sequencing the reference and sample in different lanes
has little effect on the resolution of the method. We
sequenced the reference in lane 1 in multiplex with the
0.1% synthetic mixture while the 0.3% and 1% mixtures
were sequenced in lane 2 and the 10% and 100% mix-
tures were sequenced in lane 3. We find that for variants
with 0.3% MAF and above, sequencing the reference in a
different lane still allows for high sensitivity and specifi-
city (Table 1). Thus, users can maximize capacity by
sequencing the reference replicates in only one lane
while sequencing multiple lanes of clinical samples, with
a moderate decrease in resolution.Comparison of calls on MiSeq and GAIIx platform
When identical clinical libraries were sequenced on the
Illumina MiSeq and GAIIx platforms, RVD was able to
detect many rare (<1%) mutations that were called on
the GAIIx (Additional file 2: Figures S2 S3). There was
an increase in the site-specific standard deviation
(0.005% vs 0.09%) but a slightly lower average error rate
(0.055% vs 0.05%) in the MiSeq data at a base quality
threshold of 30. The MiSeq run generated 9.5x106 37 bp
aligned single-end reads for an average coverage of
11,723 across the data set with average sample-specific
coverage ranging from 1,854 to 34,976 reads. The GAIIx,
comparatively, produced an average coverage of 103,130
with sample-specific coverage ranging from 13,535 to
341,523 reads.
We identified a set of concordant variants as those
variants that were called similarly on all four GAIIx BN1
replicates (two each in lane 1 and 2). This set was used
to estimate sensitivity and specificity of MiSeq calls. The
sensitivity is 57.1% and the specificity is 99.5% with a
quality score threshold of 30 and no resolution threshold
(Figure 3).
There was a 58.2% concordance of BN1 variant calls
within the MiSeq platform compared with 79.1% con-
cordance within the GAIIx with no minimum resolution
threshold and a quality score threshold of 30. We find a
42.5% concordance between BN1 variants called with
consensus on the GAIIx and those called with consensus
on the MiSeq. Lower levels of concordance and sensitiv-
ity may be due to the fact that this data was collected on
an early iteration of the MiSeq platform with shorter
reads and lower average qualities than newer MiSeq
data. In addition, this early Miseq run had 10-fold lower
depth of coverage compared to the GAIIx.Conclusions
We provide here a tool for identifying rare mutations
directly from targeted resequencing data sets. The im-
proved resolution to detect rare mutations using this
tool can aid in our understanding of the relationship
between rare, novel mutations that occur in samples
demonstrating genetic heterogeneity. For example, this
genetic diversity is seen in infectious viruses such as
HIV and HCV. In the future, we plan to investigate
RVD’s statistical power using lower depth (<10,000)
samples for use on longer genomic regions. These next
steps will allow us to apply RVD’s high sensitivity and
specificity to improve understanding of rare mutations
in cancer genes and the complex genetics involved in
cancer tumor evolution.Availability and requirements
Project name: RVD
Project home page: http://dna-discovery.stanford.edu/
software/rvd/
Operating system(s): Linux, Mac OS X
Programming Language(s): MATLAB
Other requirements: Samtools 0.1.18, MATLAB com-
piler runtime version 7.17 (provided in the program
package), x11
License:
Any restrictions to use by non-academics: NoneAdditional files
Additional file 1: Containing a detailed user guide explaining how
to download and run the RVD program.
Additional file 2: Containing supplementary figures.Abbreviations
MAF: Minor allelic fraction; BAM: Binary alignment map; HIV: Human
immunodeficiency virus; HCV: Hepatitis C virus.
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